Provided by Tiger Trade Technology Pte. Ltd.

Apogee Therapeutics

74.68
-0.6900-0.92%
Post-market: 74.680.00000.00%16:58 EDT
Volume:714.37K
Turnover:53.43M
Market Cap:5.19B
PE:-17.72
High:76.50
Open:75.06
Low:73.27
Close:75.37
52wk High:84.56
52wk Low:26.20
Shares:69.49M
Float Shares:52.45M
Volume Ratio:0.75
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.2155
EPS(LYR):-4.2155
ROE:-31.57%
ROA:-21.11%
PB:5.74
PE(LYR):-17.72

Loading ...

Funding for Risky Biotechs Is Returning -- WSJ

Dow Jones
·
Jan 13

Apogee Therapeutics Chief Medical Officer Carl Dambkowski Reports Disposal of Common Shares

Reuters
·
Jan 10

Apogee Therapeutics Initiated at Peer Perform by Wolfe Research

Dow Jones
·
Jan 08

UBS Initiates Apogee Therapeutics at Buy With $100 Price Target

MT Newswires Live
·
Jan 07

BUZZ-U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, Tesla

Reuters
·
Jan 07

Apogee Therapeutics Inc : Btig Raises Target Price to $137 From $128

THOMSON REUTERS
·
Jan 07

BUZZ-U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin

Reuters
·
Jan 06

BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge

Reuters
·
Jan 06

Apogee Therapeutics Shares Add 1.7% Premarket After Asthma Drug Shows Promise in Early Trial

THOMSON REUTERS
·
Jan 06

BUZZ-Apogee Therapeutics rises as asthma drug shows promise in early trial

Reuters
·
Jan 06

Apogee Therapeutics Announces Positive Interim Results From Phase 1B Trial of Zumilokibart (Apg777), Its Potentially Best-in-Class Anti-Il-13 Antibody, in Patients With Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

THOMSON REUTERS
·
Jan 06

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

GlobeNewswire
·
Jan 06

U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure

Reuters
·
Jan 06

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

GlobeNewswire
·
Jan 06

Apogee Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Jan 05

Apogee Therapeutics CFO Jane Henderson Reports Disposal of Common Shares

Reuters
·
Dec 24, 2025

Apogee Therapeutics Initiated at Overweight by Stephens & Co.

Dow Jones
·
Dec 17, 2025

Stephens Initiates Coverage on Apogee Therapeutics With Overweight Rating, $95 Price Target

MT Newswires Live
·
Dec 17, 2025

BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026

Reuters
·
Dec 17, 2025

U.S. RESEARCH ROUNDUP-Airbnb, Garrett Motion, Range Resources

Reuters
·
Dec 17, 2025